Decreased levels of CYP7A1, CYP27A, and FGF-19 have been observed in NAFLD patients, resulting in decreased cholesterol degradation, further increasing FC accumulation in the liver and accelerating the progression of NAFLD [57]. The gene discussed is CYP7A1; the disease is metabolic dysfunction-associated steatotic liver disease.